ST. LOUIS, MO, July 31, 2018 – Crux Quality Solutions (CruxQS™) announced today
that the UK’s Southampton General Hospital will collaborate with CruxQS™ on
development of FlowBoard™, an intelligent workflow management solution for
The main site of the NHS Trust: Southampton General Hospital is one of the UK’s
largest integrated cancer centers and a global leader in clinical research. The center
treats around 4,000 patients with a new diagnosis of cancer each year and of those
2,200 patients per year with radiotherapy and provides multiple modalities of
treatments for the majority of cancer types. The versatility of their operation along
with UKs strict timelines for cancer patients makes efficiency and safety an
important necessity that will benefit by using the FlowBoard™ platform.
FlowBoard™ is an intelligent workflow management solution for radiation
oncology, which integrates with Record and Verify systems, popular treatment
planning systems and other systems that are part of the oncology department.
Integrating and visually presenting this information along with notification of
bottlenecks & other proactive predictive analytics mitigate communication errors,
improve efficiency and enable care teams with easy access to relevant data to make
decisions. For patients it means a smoother treatment experience, quick start times
and good quality of care.
The immediate step in the strategic alliance is to work with the radiotherapy
physics team to integrate the necessary tools into the FlowBoard™ system for
benefits of the cancer patients around the workflow. Installation and training of the
FlowBoard™ system at Southampton General Hospital will commence immediately
to expedite the optimization and development process of FlowBoard™.
"I am excited that University Hospital Southampton NHS Foundation Trust has
joined us in our efforts towards optimizing the workflow for cancer care providers
and patients”, said Dharanipathy Rangaraj, PhD, Crux Quality Solutions Founder &
CEO. “Using FlowBoard to reduce care delays, improved efficiency and safety in the
international market is one of the most exciting challenges to date for us”, said Dr.
“Combining the innovation capability of CruxQS™ and the vast clinical knowledge of
the Radiotherapy Physics team at Southampton General Hospital will no doubt
ensure that this collaboration will be a great success.” “We look forward to working
with the CruxQS™ team to help them with bringing this innovative technology to the
UK market”, said Nael Clarke, Commercial Director for University Hospital
Southampton NHS Foundation Trust.
Chief Marketing Officer